#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention
<p><a href= "https://peterattiamd.com/obicetrapib/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> View the Show Notes Page for This Episode</a></p> <p><a href= "https://peterattiamd.com/subscribe/?utm_source=podcast-feed&%20obicetrapib%20=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> Become a Member to Receive Exclusive Content</a></p> <p><a href= "https://peterattiamd.com/newsletter/?utm_source=podcast-feed&utm_medium=referral&utm_campaign=260316-pod-obicetrapib&utm_content=260316-pod-obicetrapib-podfeed"> Sign Up to Receive Peter's Weekly Newsletter</a></p> <p>In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why …
N'eo ket bet treuzskrivet an taol-mañ c'hoazh
Arverañ STT.ai evit treiñ an taol-kaoz-mañ gant AI. Degas skrid a-feson gant dizoleiñ ar c'haozeerien, ar stampoù amzer, hag ezporzhiañ e meur a mentrezh.